Cybin (CYBN) EBIT : $-96.59 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Cybin EBIT?

Cybin's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-43.01 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-96.59 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cybin's annualized ROC % for the quarter that ended in Sep. 2024 was -237.19%. Cybin's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1,519.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cybin's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -97.82%.

Cybin EBIT Historical Data

The historical data trend for Cybin's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin EBIT Chart

Cybin Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

-25.63

-50.43

-37.65

-58.24

Cybin Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial													-10.28	-20.14	-18.61	-14.83	-43.01

Competitive Comparison of Cybin's EBIT

For the Biotechnology subindustry, Cybin's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cybin's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cybin's EV-to-EBIT falls into.

Cybin EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-96.59 Mil.

Cybin (AMEX:CYBN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cybin's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-172.02 * ( 1 - 0% )	/	( (70.608	+	74.438)	/ 2 )
=	-172.02	/	72.523
=	-237.19 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	207.696	-	3.359	-	( 133.729	-	max(0, 3.513	-	146.493	+	133.729	))
=	70.608

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	193.704	-	5.345	-	( 113.921	-	max(0, 5.443	-	131.942	+	113.921	))
=	74.438

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cybin's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-172.02	/	( ( (0.314 + max(9.406, 0))	+	(0.253 + max(12.676, 0)) )	/	2 )
=	-172.02	/	( ( 9.72	+	12.929 )	/	2 )
=	-172.02	/	11.3245
=	-1,519.01 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.37	+	0	+	9.394)	-	(3.359	+	0	+	-0.00099999999999989)
=	9.406

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.064	+	0	+	13.957)	-	(5.345	+	0	+	0)
=	12.676

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cybin's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-96.586	/	98.740
	=	-97.82 %

Cybin EBIT Related Terms

Thank you for viewing the detailed overview of Cybin's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cybin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

R7E:Germany CYBN:Canada

Address

100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9

Website

https://www.cybin.com

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.